Anti-BRAF mutation drug resistance enhances EGFR expression in melanomas
收藏官方服务：
资源简介：
Anti-BRAF mutation drug resistance enhances EGFR expression in melanomas
应用场景：
创建时间：
2014-12-17
相关数据集
DataSheet_7_Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma.pdf
PurposeType 2 diabetes mellitus (T2DM) is among the risk factors for the occurrence and development of cancer. Metformin is a potential anticancer drug. Epidermal growth factor receptor (EGFR) plays a
NIAID Data Ecosystem60
Small_molecule_inhibitors_in_melanoma___Kenski___Kong___WES__mouse_
Small-molecule inhibitors targeting the most commonly activated pathway in melanoma, MAPK pathway (either alone or in combination) are already given to melanoma patients for few years, and initially r
NIAID Data Ecosystem60
Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling
Despite the increasing number of effective anti-cancer therapies, successful treatment is limited by the development of drug resistance. While the contribution of genetic factors to drug resistance is
NIAID Data Ecosystem50
Disrupting ATF4 expression mechanisms provides an effective strategy for BRAF-targeted melanoma therapy (Knockdown Series). Disrupting ATF4 expression mechanisms provides an effective strategy for BRAF-targeted melanoma therapy (Knockdown Series)
BRAF V600 mutation influences cellular signaling pathways for melanoma development. Here, we show that mutated BRAF plays an essential role in the adaptive stress response following activation of gene
NIAID Data Ecosystem60
Expression data from BRAF-mutant melanoma cell lines
Melanoma cell lines were assessed for differences in gene expression patterns between the lines sensitive and resistant to BRAF and MEK inhibitor drugs. 22 BRAF-mutant melanoma cell lines were assess
NIAID Data Ecosystem50
